May 22 (Reuters) - Evaxion A/S EVAX.O:
EVAXION DOSES FIRST PATIENT IN EXTENSION OF PHASE 2 TRIAL EXPLORING THE FULL POTENTIAL OF AI-DESIGNED PERSONALIZED CANCER VACCINE EVX-01
EVAXION A/S - TRIAL ON TRACK FOR TWO-YEAR DATA READOUT IN H2 2025
Source text: ID:nGNX1lvH1W
Further company coverage: EVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.